Laplace TTVR Trial Enrolls 400 Patients After FDA IDE Green Light

For the biotech and pharma sector, FDA IDE approval for a novel transcatheter heart valve device is a pivotal de-risking event. Laplace's TRIUMPH trial not only validates the clinical promise of its TTVR system but also signals investor confidence, as top-tier centers like Mayo Clinic and Vanderbilt sign on as principal investigators. With severe tricuspid regurgitation affecting 1.6 million Americans and few approved devices, the market potential is substantial, making Laplace a company to watch in the structural heart space.

Laplace Interventional has reached a critical regulatory milestone with the U.S. FDA granting an Investigational Device Exemption (IDE) for the TRIUMPH pivotal trial, clearing the path for a large-scale clinical evaluation of its transcatheter tricuspid valve replacement (TTVR) system. Announced on June 29, 2026, the approval marks a significant step toward addressing severe tricuspid regurgitation (TR), a condition that remains undertreated due to high surgical risk and limited device options. The TRIUMPH trial is a prospective, multicenter study designed to assess the safety and effectiveness of the Laplace TTVR system, with a target enrollment of approximately 400 patients across up to 75 sites in a randomized 2:1 arm against commercially available TTVR. Additionally, a single-arm registry of up to 150 patients who are ineligible for commercial TTVR and suboptimal for transcatheter edge-to-edge repair (TEER) will capture real-world data in a harder-to-treat population. The trial design reflects both FDA expectations for rigorous comparative evidence and a recognition that not all TR patients can access existing technologies.

“

FDA granting an Investigational Device Exemption (IDE) for the TRIUMPH pivotal trial, clearing the path for a large-scale clinical evaluation of its transcatheter tricuspid valve replacement (TTVR) system.

The tricuspid valve has long been called the 'forgotten valve' in interventional cardiology, with TR affecting an estimated 1.6 million Americans, yet fewer than 10,000 tricuspid surgeries performed annually due to prohibitive risks. Transcatheter approaches have recently emerged, led by Edwards Lifesciences' EVOQUE system and Abbott's TriClip TEER device, both already commercialized. Laplace positions its TTVR as a differentiated solution, touting a unique design that builds on promising early feasibility study (EFS) data. While the company has not publicly disclosed detailed EFS results, the three global principal investigators – Dr. Charanjit Rihal of Mayo Clinic, Dr. Kashish Goel of Vanderbilt, and Dr. Brandon Jones of Providence St. Vincent – described the data as 'very impressive' and indicative of 'excellent clinical outcomes.' Their institutions were the top enrollers in the EFS, lending credibility to the claims and suggesting strong investigator confidence.

The appointment of high-profile PIs from elite U.S. centers also signals Laplace's ambition to build a robust clinical and commercial foundation. Dr. Rihal, a veteran interventional cardiologist, highlighted the potential for 'new options for patients with advanced TR.' Dr. Goel emphasized the 'significant unmet need' Laplace aims to solve, while Dr. Jones noted the desperation of patients. Such language, while part of a press release, underscores the clinical gap and the enthusiasm around TTVR. The trial's 2:1 randomization in favor of the Laplace device over commercial TTVR is notable; it suggests a superiority design, though the exact statistical plan will be revealed in the protocol. The inclusion of a registry arm for TEER-ineligible patients also helps build a broader evidence base, potentially supporting a label expansion later.

The tricuspid device market is rapidly evolving. Edwards' EVOQUE received FDA approval in 2024 for treating severe TR, and Abbott's TriClip is widely used in Europe and the U.S. under certain indications. Laplace enters a competitive arena, but with a unique valve design that may offer advantages in anchoring, sealing, or delivery – details the company has not fully disclosed. The TRIUMPH trial, if successful, could position Laplace as a key player in a market projected to reach several billion dollars by 2030. However, pivotal trials in the tricuspid space have historically faced challenges with patient selection, anatomical variability, and endpoint definition. The FDA's acceptance of the IDE signals that the preliminary data was sufficient to justify a large trial, but the road to PMA approval remains long.